Evidence map›Paper›PMID 29958841›Full record

ArticleBiochemical pharmacology2018

Interactions of endocannabinoid virodhamine and related analogs with human monoamine oxidase-A and -B.

Pankaj Pandey, Narayan D Chaurasiya, Babu L Tekwani, Robert J Doerksen

Abstract read
In one paragraph

Article in Biochemical pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Promising selective MAO-B inhibition by sesamin, a lignan fromSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2020
    Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Pankaj PandeyDepartment of BioMolecular Sciences and National Center for Natural Products Research, Research Institute of Pharmaceutical Sciences, School of Pharmacy, University of Mississippi, University, MS 38677, United States.
Narayan D ChaurasiyaNational Center for Natural Products Research, Research Institute of Pharmaceutical Sciences, School of Pharmacy, University of Mississippi, University, MS 38677, United States.
Babu L TekwaniDepartment of BioMolecular Sciences and National Center for Natural Products Research, Research Institute of Pharmaceutical Sciences, School of Pharmacy, University of Mississippi, University, MS 38677, United States; National Center for Natural Products Research, Research Institute of Pharmaceutical Sciences, School of Pharmacy, University of Mississippi, University, MS 38677, United States. Electronic address: btekwani@southernresearch.org.
Robert J DoerksenDepartment of BioMolecular Sciences and National Center for Natural Products Research, Research Institute of Pharmaceutical Sciences, School of Pharmacy, University of Mississippi, University, MS 38677, United States; National Center for Natural Products Research, Research Institute of Pharmaceutical Sciences, School of Pharmacy, University of Mississippi, University, MS 38677, United States. Electronic address: rjd@olemiss.edu.
University of Mississippi · US

Funding

Center of Research Excellence in Natural Products Neuroscience (CORE-NPN)P20GM104932 · NIGMS · UNIVERSITY OF MISSISSIPPI · PI MAJUMDAR, SOUMYAJIT · 2012 to 2016
$10.0M
RENOVATION OF FOURTH FLOOR OF FASER HALLC06RR014503 · NCRR · UNIVERSITY OF MISSISSIPPI · PI WELLS, BARBARA G · 1999 to 1999
–
NCRR NIH HHS C06 RR014503NIGMS NIH HHS P20 GM104932
6 · The paper itself

Abstract

The endocannabinoid system plays an important role in the pathophysiology of various neurological disorders, such as anxiety, depression, neurodegenerative diseases, and schizophrenia; however, little information is available on the coupling of the endocannabinoid system with the monoaminergic systems in the brain. In the present study, we tested four endocannabinoids and two anandamide analogs for inhibition of recombinant human MAO-A and -B (monoamine oxidase). Virodhamine inhibited both MAO-A and -B (IC

Indexed as

AnimalsCannabinoid Receptor ModulatorsCannabinoidsEndocannabinoidsHumansMolecular Docking SimulationMonoamine OxidaseMonoamine Oxidase InhibitorsPC12 CellsRatsCannabinoid Receptor ModulatorsCannabinoidsEndocannabinoidsMonoamine Oxidasemonoamine oxidase A, humanMonoamine Oxidase Inhibitorsvirodhamine2-Arachidonoylglycerol (PubChem CID: 5282280)4-Hydroxyquinoline (PubChem CID: 69141)Anandamide (PubChem CID: 5281969)Clorgyline (PubChem CID: 28767)Dimethyl sulfoxide (PubChem CID: 679)DockingEndocannabinoidsEnzyme kineticsKynuramine dihydrobromide (PubChem CID: 16219543)MAO-BNoladin ether (PubChem CID: 6483057)Oleylethanolamide (PubChem CID: 5283454)Phenelzine sulfate (PubChem CID: 61100)Potassium phosphate (PubChem CID: 516951)R-(−)-Deprenyl hydrochloride (PubChem CID: 5195)(R)-(+)-Methanandamide (PubChem CID: 6321351)Safinamide (PubChem CID: 131682)VirodhamineVirodhamine trifluoroacetate (PubChem CID: 91691131)

Identifiers

PMID29958841
PMCPMC6298601
OpenAlexW2810236697

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.